Development of a novel polysaccharide-based iron oxide nanoparticle to prevent iron accumulation-related osteoporosis by scavenging reactive oxygen species

Pengjun Yu,Liming Zheng,Peng Wang,Senlin Chai,Yibo Zhang,Tianshu Shi,Lei Zhang,Rui Peng,Caoxing Huang,Baosheng Guo,Qing Jiang

DOI: https://doi.org/10.1016/j.ijbiomac.2020.10.016

IF: 8.2

2020-12-01

International Journal of Biological Macromolecules

Abstract:<p>In this work, the biological polysaccharide-based antioxidant polyglucose-sorbitol-carboxymethyl ether (PSC) was used as the precursor to synthesize Fe₂O₃@PSC nanoparticles, which are expected to scavenge excess reactive oxygen species (ROS) to inhibit osteogenesis and promote osteoclast differentiation in iron accumulation (IA)-related osteoporosis. The Fe₂O₃@PSC nanoparticles obtained were of a uniform particle size of 7.3 nm with elemental O/Fe/Cl/C at a ratio of 190:7:2:88. In addition, the Fe₂O₃@PSC nanoparticles showed the ability to supply equivalent amounts of iron as the typical iron agent ferric ammonium citrate (FAC) <em>in vitro</em> and <em>in vivo</em>. Importantly, the Fe₂O₃@PSC nanoparticles not only induced antioxidative MC3T3-E1 and Raw 264.7 cells to scavenge ROS but also promoted osteogenic differentiation by activating Akt-GSK-3β-β-catenin and inhibiting osteoclast differentiation by inhibiting the MAPK and NF-κB pathways <em>in vitro</em>. <em>In vivo</em>, no IA-related osteoporosis was induced in a mouse model when enough iron was supplied by the Fe₂O₃@PSC nanoparticles. Overall, the biological polysaccharide-based antioxidant PSC can supply iron and prevent IA-related osteoporosis, indicating that it is a promising novel iron agent for applications to treat iron deficiency diseases.</p>

polymer science,biochemistry & molecular biology,chemistry, applied

What problem does this paper attempt to address?

This paper aims to address the issue of iron overload-related osteoporosis. Specifically, the authors developed a novel polysaccharide-based iron oxide nanoparticle (Fe2O3@PSC) to inhibit osteoporosis caused by iron overload by scavenging reactive oxygen species (ROS). These nanoparticles can not only serve as an iron source to supplement iron but also reduce ROS generation through their antioxidant properties, thereby preventing the negative impact of iron overload on bone metabolism. In vitro experiments demonstrated that these nanoparticles exhibit good biocompatibility and iron supply capability, effectively inhibit ROS generation at the cellular level, promote osteoblast differentiation, and inhibit osteoclast differentiation. In in vivo experiments, these nanoparticles also showed the effect of preventing iron overload-related osteoporosis. Therefore, this novel nanoparticle is expected to become a potential new drug for the treatment of iron deficiency diseases.